(Q39653062)

13 September 2017

ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis (English)

1 reference

13 September 2017

1 reference

1 reference

1 reference

Houguang He

1

1 reference

13 September 2017

Conghui Han

series ordinal

2

1 reference

13 September 2017

Lin Hao

series ordinal

3

1 reference

13 September 2017

Guanghui Zang

series ordinal

4

1 reference

13 September 2017

language of work or name

1 reference

12 May 2016

1 reference

13 September 2017

1 reference

13 September 2017

12

1 reference

13 September 2017

1

1 reference

13 September 2017

83-88

1 reference

The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation

13 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Urine cytology and adjunct markers for detection and surveillance of bladder cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

The present and future burden of urinary bladder cancer in the world

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Voided urinary cytology in bladder cancer: is it time to review the indications?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Statistical aspects of the analysis of data from retrospective studies of disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Measuring inconsistency in meta-analyses

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Meta-analysis in clinical trials

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Diagnostic significance of atypical category in the voided urine samples: A retrospective study in a tertiary care center

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Diagnostic tests 3: receiver operating characteristic plots

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

A generalized weighting regression-derived meta-analysis estimator robust to small-study effects and heterogeneity

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Cytology of the urinary tract. A modern investigation method?

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Random-effects model for meta-analysis of clinical trials: an update

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4906922

Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative

21 August 2018

1 reference

12 December 2020

uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses

1 reference

12 December 2020

Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark

1 reference

12 December 2020

Urine cytology discrepancies: frequency, causes, and outcomes

1 reference

12 December 2020

Diagnostic significance of 'atypia' in instrumented versus voided urine specimens

1 reference

12 December 2020

Analysis of atypical urine cytology in a tertiary care center

1 reference

12 December 2020

ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

1 reference

12 December 2020

Combinations of urine-based tumour markers in bladder cancer surveillance

1 reference

12 December 2020

Immunocytology in the assessment of patients with asymptomatic microhaematuria

1 reference

12 December 2020

Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States

1 reference

12 December 2020

Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer

1 reference

12 December 2020

The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder

1 reference

12 December 2020

Identifiers

0 references

1 reference

13 September 2017

PubMed publication ID

27347104

1 reference